Autoplaque vs ElucidVivo A.3
AI Verdict
Choose Autoplaque if…
Choose Autoplaque if your primary need is a comprehensive, AI-powered quantitative analysis of coronary plaques and luminal stenoses from CT angiography images to aid in general heart attack risk prediction and treatment guidance. It provides automated vessel, plaque, and lumen segmentation, offering a foundational assessment of coronary artery disease.
View Autoplaque →Choose ElucidVivo A.3 if…
Choose ElucidVivo A.3 if you require a more in-depth, AI-powered analysis of arterial plaque composition and stability, particularly for advanced atherosclerosis patient stratification and optimizing treatment decisions. Its unique ability to objectively quantify specific plaque components like Lipid-Rich Necrotic Core (LRNC) and its validation against ground-truth histology make it ideal for understanding plaque vulnerability and deriving FFRct.
View ElucidVivo A.3 →When choosing between Autoplaque and ElucidVivo A.3, physicians should consider their primary focus in cardiac CT angiography analysis. Autoplaque, developed by Cedars-Sinai AIM, excels in quantitative analysis of coronary plaques and luminal stenoses, providing measurements of vessel diameter and area, and offering automated vessel, plaque, and lumen segmentation. It’s a workstation-based solution ideal for clinicians prioritizing a comprehensive overview of coronary anatomy and pathology to aid in heart attack risk prediction and treatment guidance.
ElucidVivo A.3 by Elucid Bioimaging, on the other hand, specializes in detailed quantitative analysis of arterial plaque composition and stability. It objectively quantifies specific plaque components like Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications, with validation against histology. This tool is best suited for physicians who require in-depth insights into plaque characteristics for atherosclerosis patient stratification and optimizing treatment decisions, particularly those interested in plaque stability and fractional flow reserve (FFRct) derivation.
The key practical difference lies in their analytical depth: Autoplaque provides a broader view of coronary plaque and stenosis, while ElucidVivo A.3 offers a more granular analysis of plaque composition. Therefore, a physician primarily focused on general coronary assessment and stenosis measurement might lean towards Autoplaque. In contrast, a physician needing detailed plaque characterization and stability assessment for advanced patient stratification would likely find ElucidVivo A.3 more beneficial. Both are FDA-cleared, but their distinct analytical strengths cater to different clinical priorities in cardiovascular care.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Autoplaque | ElucidVivo A.3 |
|---|---|---|
| Pricing | Not disclosed | Contact for pricing |
| Deployment | Workstation-based software, runs on Windows or Mac computer platforms | Software application, likely on-premise or cloud-based (standard for medical imaging software, not explicitly detailed, but integrates with PACS/EMR). |
| FDA Status | 1 AI-estimated | 1 AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
AutoplaqueAutoplaque is a workstation-based software compatible with Windows or Mac platforms, offering clinicians the ability to review and edit automated vessel, plaque, and lumen segmentations. This direct control and interactive functionality provide a hands-on user experience for detailed post-processing. While ElucidVivo A.3 integrates with PACS/EMR, Autoplaque's explicit workstation deployment and editable segmentations offer a clear advantage in direct user interaction and flexibility for individual clinicians.
Clinical Value
ElucidVivo A.3ElucidVivo A.3 provides a more advanced and comprehensive clinical value by objectively quantifying specific plaque components like Lipid-Rich Necrotic Core (LRNC) and deriving fractional flow reserve (FFRct), which are critical for assessing plaque stability and hemodynamic significance. Its validation against ground-truth histology provides a strong basis for its detailed plaque characterization, aiding in more precise patient stratification and treatment decisions. While Autoplaque also quantifies plaque, ElucidVivo's depth in characterizing plaque composition and function, backed by histology, gives it an edge.
Pricing & Value
TieBoth Autoplaque and ElucidVivo A.3 have undisclosed pricing, stating 'not disclosed' or 'contact for pricing.' This lack of transparency for both tools prevents a meaningful head-to-head comparison of their respective value propositions or cost-effectiveness.
Enterprise Readiness
ElucidVivo A.3ElucidVivo A.3 explicitly states or strongly implies integration with PACS/EMR systems and HIPAA compliance, which are crucial for seamless deployment and data management within large healthcare enterprises. In contrast, Autoplaque is described as workstation-based software with unspecified HIPAA compliance and BAA availability, potentially posing challenges for widespread enterprise integration and centralized management.
Innovation
ElucidVivo A.3ElucidVivo A.3 demonstrates greater innovation by uniquely quantifying specific plaque components like Lipid-Rich Necrotic Core (LRNC) and deriving fractional flow reserve (FFRct) based on vessel wall vasodilative capacity. Its distinction as the 'first FDA-Cleared and CE-marked non-invasive software to quantify atherosclerotic plaque characteristics compared to histopathology' highlights its pioneering approach in providing deeper, histologically validated insights into plaque stability and hemodynamic impact.
Support & Docs
TieNeither Autoplaque nor ElucidVivo A.3 provides sufficient public information regarding their specific support channels, service level agreements, or comprehensive user documentation. While user manuals are implied for both, there is no basis to distinguish them in terms of overall support and documentation quality or availability.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Autoplaque | ElucidVivo A.3 |
|---|---|---|
| Product Name | Autoplaque | ElucidVivo A.3 |
| Company | Cedars-Sinai Medical Center: AIM | Elucid Bioimaging |
| Core Function | AI-powered software for quantitative analysis of coronary plaques and luminal stenoses from CT angiography images, aiding in heart attack risk prediction and treatment guidance. | AI-powered medical image analysis system that provides quantitative analysis of arterial plaque composition and stability from CT angiography, assisting in atherosclerosis patient stratification and optimizing treatment decisions. |
| Specific Plaque Analysis | AI-powered quantitative analysis of atherosclerotic plaque; detection and characterization of coronary artery plaque; measurement of luminal stenoses. | Objectively quantifies Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications from CT images; visualizes lesion-level plaque composition; derives fractional flow reserve (FFRct). |
| Supported Specialties | Cardiology, Radiology | Cardiology, Radiology, Vascular Surgery |
Videos
Demos, reviews, and walkthroughs featuring Autoplaque and ElucidVivo A.3.